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Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer with poor overall survival.
New therapeutic strategies that target specific molecular lesions driving advanced disease are needed. Herein we
demonstrate the utility of the chicken chorioallantoic membrane (CAM) assay for in vivo human HNSCC tumor
growth and metastasis and the tumor suppressive effects of a new chemotherapeutic agent.
Methods: We tested anti-metastatic effects of a WNT pathway inhibitor, WNT974 (also known as LGK974), which
targets porcupine (PORCN) the palmityl-transferase that is essential for secretion of Wnt proteins. CAM assays were
performed with 8 HNSCC cell lines: UM-SCC-1, UM-SCC-10A, UM-SCC-10B, UM-SCC-11A, UM-SCC-14A UM-SCC-17A,
UM-SCC-17B, UM-SCC-25, and UM-SCC-34.
Results: UM-SCC-1 (University of Michigan Squamous Cell Carcinoma cell line) CAM xenografts contain CD44+ and
ALDH+ cancer stem cell (CSC) proportions similar to UM-SCC-1 mouse xenografts supporting the applicability of
the CAM assay for study of CSCs. Inhibition of WNT signaling by the PORCN inhibitor WNT974 reduced metastatic
spread of UM-SCC cells, especially in UM-SCCs with Notch1 deficiency.
Conclusions: Our data demonstrate decreased tumor growth and metastases in tumors from cell lines that
showed in vitro responses to WNT974, providing evidence that this agent may have a role in future HNSCC therapy.
Keywords: In vivo cancer model, WNT pathway inhibition, WNT974, Human squamous cell carcinoma,
Chorioallantoic membrane, UM-SCC, Cell lines, NOTCH1 mutation
Background
Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common form of cancer worldwide [1].
Despite therapeutic strides made in the field of oncology
in recent years, the prognosis of HNSCC remains very
poor, in large part due to the highly invasive nature of
this cancer which often results in extensive local
invasion, early dissemination into regional lymph nodes,
and metastatic spread of the disease [2]. At the time of
diagnosis, two-thirds of patients already have locoregion-
ally advanced disease, defined as Stage 3 or 4. The over-
all five year overall survival rates for all stages of larynx
and oral and pharynx cancer ranges from 63–66 percent
respectively [3]. For patients with advanced disease the
introduction of adjuvant concurrent chemoradiotherapy
has improved survival by roughly 12 %, which corre-
sponds to an improvement in overall 5 year survival
from 45 % in 1973 to 53.2 % in 2005 [4]. Given these
considerations, there is a clear need for therapeutic ad-
vances in this field, and those that will have the most
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meaningful impact are likely to come in the form of mo-
dalities that treat the genetic drivers of advanced-staged
disease [5].
The Wnt signaling pathway is an appealing target, as
this developmental pathway has been implicated in a
large number of human cancers, with recent evidence
for an oncogenic role in HNSCC [6]. Deregulation of
Wnt signaling from mutation or abnormal expression of
pathway components has been implicated to play a role
in invasive growth patterns in HNSCC [7]. Normally,
the Wnt signal transduction pathway leads to activation
of pathways regulating the cytoskeleton, cellular calcium
levels and beta-catenin protein expression and transcrip-
tional activation (reviewed in [8–13]). Briefly, the path-
way is activated by either autocrine or paracrine
signaling through a combination of up to nineteen dif-
ferent Wnt ligands acting on Frizzled receptors. In the
absence of Wnt receptor activation, two scaffolding
tumor suppressor proteins in the beta-catenin destruc-
tion complex called adenomatous polyposis coli (APC)
and axin bind to beta-catenin enabling the kinases CK1
and glycogen synthase kinase 3 to sequentially phos-
phorylate the amino terminus of beta-catenin. The
resulting phosphorylated footprint targets beta-catenin
for proteasomal degradation. Once activated by Wnt,
the Frizzled receptors inhibit the destruction complex
through incompletely understood mechanisms. To-
gether, this leads to an accumulation of β-catenin pro-
tein, which can then translocate to the nucleus to form a
complex with LEF/TCF proteins to regulate transcrip-
tion of proliferation associated genes.
A small molecule inhibitor of the Wnt-pathway,
LGK974, was recently described [14]. The drug name
LGK974 has been renamed and is now synonymous with
the name WNT974. WNT974 is the name that will be
used to reference this compound in this manuscript.
WNT974 compound is a potent small molecule in-
hibitor of Porcupine (PORCN), a membrane-bound
O-acyltransferase that adds a palmityol group to Wnt
ligands. This modification is essential for Wnt secre-
tion and Frizzled activation. In vitro studies showed a
potent inhibitory effect of WNT974 on Wnt signal-
ing, as evidenced by decreased expression of down-
stream target genes, such as AXIN2, as well as
reduced Wnt-dependent phosphorylation of LRP6. Of
the 96 HNSCC cell lines analyzed, 31 demonstrated a
pharmacodymanic (PD) AXIN2 mRNA reduction re-
sponse and were thus considered as cell lines that
were responsive to treatment with WNT974. Interest-
ingly, there was an enriched rate of response to
WNT974 among head and neck cancer cell lines with
Notch1 loss-of-function (LOF) mutations [14].
Like Wnt, Notch is also a developmental pathway
gene that has recently been implicated in HNSCC
tumorigenesis [15–17]. While Notch gain-of-function
mutations have been demonstrated in T-cell leuke-
mias and some other forms of cancer, a tumor sup-
pressor role for the Notch pathway has also been
suggested in a number of human cancers, including
in HNSCC, in which NOTCH1 LOF mutations were
found in 10–15 % of tumors and abnormalities of the
Notch pathway in 66 % of patients [18]. The Notch
pathway has been proposed to have an inhibitory ef-
fect on Wnt signaling in some cell types [19, 20] with
evidence suggesting that activated Notch1 signaling
suppresses β-catenin signaling in cells that should
normally undergo differentiation from the basal layer
of the epidermis [17]. With these considerations in
mind, we designed an experiment to test the effect-
iveness of Wnt pathway inhibition with WNT974
on in vivo tumor growth and distant metastasis
using the chick chorioallantoic membrane (CAM)
assay and human squamous cell carcinoma cell
lines. The chick CAM is a multilayered epithelium
that consists of ectoderm, mesoderm, and endo-
derm, as well as extracellular matrix proteins such
as laminin and type I collagen, a composition that
mimics the tumor environment in humans [21].
Consequently, CAM assays are a well-established in
vivo model that has been used to study angiogen-
esis and tumor invasion in several types of human
cancer, including prostate carcinoma, glioma, and
bowel cancer [22–24]. Here, we sought to further
illustrate the feasibility for study of head and neck
cancer cell lines using the CAM assay, determine if
HNSCC cancer stem cells (CSCs) can be identified
and isolated from primary tumors grown on the
CAM, and test the hypothesis that UM-SCC cell
line CAM xenograft tumor growth and metastasis
can be impaired by WNT974.
Methods
The aim of this study was to determine the feasibility of
the chicken chorioallantoic membrane assay for asses-
sing in vivo tumor response to a novel WNT pathway
inhibitor, WNT974, in human head and neck cancer cell
lines.
Ethics consent and permissions
The UM-SCC-1, -10A, -10B, -11A, 14A -17A, -17B, -25,
and -34 cell lines were derived in our laboratory from
human head and neck tumor explants taken during sur-
gical resection from patients treated at the University of
Michigan.The cell line donor-patients gave written in-
formed consent for the use of their tissue to create cell
lines in studies reviewed and approved by the University
of Michigan Medical School (Ann Arbor) IRBMED
institutional review board.
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Cell lines
The cell lines have been carefully characterized in our la-
boratory for HNSCC characteristics and each has been
genotyped at a minimum of 10 microsatellite markers
(Profiler Plus, Invitrogen) to confirm their unique origin
[25]. Cell lines with the same number and a letter, i.e.
were from the same donor and were derived from primary
and recurrent (UM-SCC 10A and UM-SCC-10B) or pri-
mary and metastatic (UM-SCC-17A, UM-SCC-17B),
lesions respectively. Cells were cultured in Dulbecco
modified Eagle medium (Gibco, Life Technologies) con-
taining 2 mM L-glutamine, 1 % nonessential amino acids,
1 % penicillin-streptomycin (Invitrogen), and 10 % fetal
bovine serum in a humidified atmosphere of 5 % carbon
dioxide at 37 °C. All cell lines were tested for mycoplasma
using the MycoAlert Detection Kit (Cambrex) to ensure
that they were free from contamination prior to use in
these experiments.
The use of fertilized chicken eggs is exempt from ver-
tebrate animal use approval.
Chick Chorioallantoic Membrane (CAM) Assay
Fertilized white leghorn chicken eggs were obtained
from Charles River Labs (Norwich, CT). The use of fer-
tilized chicken eggs is exempt from vertebrate animal
use approval. The eggs were kept in an incubator at 99.5
degrees Fahrenheit at a humidity range of 45–55 %.
Eight days following arrival, the embryos were assessed
for viability, performed by trans-illumination of the egg
in a dark room to identify the presence of an embryo
and surrounding blood vessels. A 1 cm2 window was
drawn on the egg shell overlying the most vascularized
area of each viable embryo. Two small holes were then
bored into the egg shell, one in the center of the window
and the other at the apex of the egg, overlying a natur-
ally occurring air pocket. A rubber pipette bulb was used
to suction a small amount of air out of this apical
pocket, causing the chorioallantoic membrane to drop
downward, away from the vent hole in the drawn win-
dow. The window was then opened using a Dremel
1100-N/25 7.2-Volt Stylus Lithium-Ion Cordless Rota
Drill (Robert Bosch Tool Company) and was covered
with a piece of clear adhesive tape to protect the embryo
and prevent dehydration. This window served as the site
for subsequent cancer cell inoculation in our preliminary
experiment, and cancer cell and drug inoculation in our
WNT974 treatment experiment (See Liu, Min et al
Translational Oncology 6:273-281, 2013 for illustrations
of the model).
Seven days after the administration of cancer cells, the
chick eggs were opened with sterile scissors, and primary
tumors were dissected out and weighed. The chick em-
bryos were then dissected, removing the lungs and livers
which were immediately placed on ice in labeled 10 mL
conical containers. The samples were stored in the -80
degree C freezer until DNA extraction.
DNA extraction and analysis
Chick embryo livers and lungs were thawed, rinsed
with 5 mL PBS and homogenized with a handheld
homogenizer (Omni International) using a sterile tip
for each sample. DNA extraction was performed using the
QIAgen DNeasy Blood & Tissue Kit (QIAGEN Group),
following the manufacturer’s specifications. Purified DNA
was quantified using a spectrophotometer, adjusted to a
concentration of 0.2ug/uL, and stored at -20 degrees C.
Quantitative PCR (qPCR) was performed on the DNA
samples using primers specific for a human Alu sequence.
Alu sequences are primate-specific, and thus their detec-
tion in chick organs represents disseminated human cells,
or cancer metastases. The copy threshold, or CT, values of
the liver and lung specimens from the eight HNSCC cell
lines were compared to the CT values of the negative con-
trols of the respective organ. Student T-tests were used to
compare the CT values of both organs of each cell line to
the respective negative control.
Applicability assay
The initial experiments were designed to demonstrate
feasibility of the CAM assay for use with HNSCC cancer
cells using eight cell lines (UM-SCC-1, -10A, -10B,
-11A, -17A, -17B, -25, and -34)..The cells were grown in
150 cm2 plastic flasks, trypsinized, counted, and resus-
pended in a mixture of 10 % matrigel (BD Biosciences)
and 90 % DMEM for a total volume of 30uL per eggs
such that each egg received 2.5 million cancer cells. The
prepared chick eggs were removed from the incubator,
and the cancer cell suspension was laid on top of the
chorioallantoic membrane using a 100uL pipette tips.
For each cell line, five eggs were each inoculated. An
additional ten eggs received a 30uL suspension of 10 %
matrigel and 90 % DMEM with no cancer cells to serve
as treatment, embryo viability, and specificity controls.
Flow cytometry
UM-SCC-1 cancer cells were administered to an add-
itional ten eggs for cancer stem cell analysis. Seven days
following cancer cell administration, primary tumors
were dissected from eight viable embryos and placed
on ice in 15 mL tubes filled with DMEM media.
Tumor tissue was minced and digested in DMEM/
F12 (Gibco) with 1x collagenase/hyaluronidase (Stem
Cell Technologies). After two hours of digestion, the
mixture was strained through a 40 μm sieve and the
cells were counted before being prepared for flow cy-
tometry. CD44 expression was detected using an
APC-conjugated antibody (BD Pharmingen). Aldehyde
dehydrogenase (ALDH) expression was detected using
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the ALDEFLUOR kit (StemCell Technologies). The
aldefluor substrate freely diffuses into cells and reacts
with human aldehyde dehydrogenase enzyme, produ-
cing a fluorescent reaction product that is propor-
tional to the enzymatic activity. This reaction does
not occur in the chicken host cells.
Tumor cells from the primary tumors of the eight vi-
able chick embryos were pooled together to gather suffi-
cient cells for an adequate assessment of CSCs in the
tumors grown on the CAM. Fluorescence-activated cell
sorting gates were established for ALDH expression
using the inhibited control (DEAB) along the fluorescein
isothiocyanate (FITC) channel with excitation and emis-
sion wavelengths of approximately 495 nm/521 nm. For
CD44 expression, cell sorting gates were established
using the APC-conjugated isotype control along the allo-
phycocyanin (APC) channel with excitation and emis-
sion wavelengths of approximately 650 nm/660 nm.
WNT974 treatment assay
To test the effect of Wnt pathway inhibition on tumor
growth and distant metastasis we first performed a dose-
finding assay with WNT974 to assess for potential tox-
icity of this pathway inhibitor on chick embryos. Three
drug concentrations were tested, 0.1 μM, 0.31 μM, and
1 μM. μM. For each drug concentration, five chick eggs
were dosed every other day for a total of four doses. An
additional five eggs were treated with 5uL DMSO (the
WNT974 vehicle) to control for vehicle toxicity to the
embryos. This assay showed minimal toxicity of these
drug concentrations on the chick embryos, with all five
embryos given 1 μM WNT974 remaining viable and
phenotypically normal through harvesting. Thus 1 μM
was selected as the treatment dose. Four UM-SCC cell
lines were selected to test the effect of WNT974 on
tumor growth on the CAM and on distant metastases to
liver and lung. Two cell lines, UM-SCC-11A and -25,
were shown via deep exome sequencing to have Notch1
mutations (UM-SCC-25 contains a nonsense LOF muta-
tion, and UM-SCC-11A contains a missense mutation),
and both exhibited a pharmacodynamic (PD) change in
AXIN2 mRNA expression in response to WNT974 dur-
ing the in vitro analysis performed by GNF. A third cell
line, UM-SCC-1, containing wildtype NOTCH1, also
showed a PD response to WNT974. The fourth line,
UM-SCC-14A, also wildtype for NOTCH1, was a PD
non-responder in vitro. The CAM assay was prepared as
described above. For each cell line, 2.5 million cells were
administered to each of 32 eggs (performed in separate
assays per cell line due to limited incubator space). Of
these, half served as treatment eggs and the other half
were vehicle control eggs. The treatment arm received
5 μL of 1 μM WNT974 once daily, every other day start-
ing the day of cancer cell inoculation for a total of four
doses. The control arm received 5uL DMSO every other
day for a total of four doses. There were also 5
manipulation-only control eggs per cell line, which were
injected with 30 μL of 10 % matrigel and 90 % DMEM
but no cancer cells. Eggs were opened seven days follow-
ing cancer cell administration, all identifiable primary tu-
mors dissected and weighed, the lung and liver tissues
harvested and DNA was purified as described above.
Statistical analysis
An a priori power calculation was performed. Given a
Type I error rate of 0.05 and power of approximately
85 %, it was determined that a sample size of at least 9
tumors in each treatment group was needed to detect a
treatment effect size of 1.5 standard deviations in magni-
tude. For each of the four cell lines, tumor weights for
the treatment and non-treatment groups were recorded
and compared using two-tailed T-tests. Given the need
to run the assay twice for each cell line due to space lim-
itations, an ANOVA model for each cell line was used to
evaluate treatment effect controlling for assay batch as a
main effect and as potential effect modifier in the model
parameterization. These analyses revealed no significant
batch effect in any of the four cell lines, thus allowing
pooling of the data from both batches. The qPCR cycle
threshold (CT) values for both the liver and lung speci-
mens in the treatment group for each cell line were
compared to the CT values of the corresponding organ
and cell line using a two-tailed T-test, generating a P-
value for both the liver and lungs in each cell line. P-
values <0.05 were considered statistically significant.
Results
UM-SCC cell lines grow and metastasize in CAM assays
Five chick embryos were implanted with cancer cells for
each of the eight UMSCC cell lines tested in this study.
For each cell line, the number of viable embryos ex-
amined for tumor growth is given following the cell
line: UM-SCC-1: 5, UM-SCC-10A: 3, UM-SCC-10B: 4,
UM-SCC-11A: 5, UM-SCC-17A: 3, UM-SCC-17B: 5,
UM-SCC-25: 5, and UM-SCC-34: 4 embryos. Of the
viable embryos, a subset was randomly chosen for primary
tumor dissection and weighing. Tumor weights ranged
from 27.4 to 82.4 mg with consistency within cell lines (all
weights within two fold of one another) and less
consistency between cell lines (up to a fourfold difference
in tumor weights). To assess the metastatic ability of these
cell lines in this assay, quantitative PCR performed on
DNA isolated from the livers of xenograft bearing an-
imals and negative control specimens are shown in
Fig. 1. This demonstrated that all eight of the cell
lines metastasized to the livers of the developing
chicks. qPCR was also performed on DNA isolated
from the chick lungs. However, only one negative
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control was included in the qPRC analysis due to the
initial poor egg viability, and therefore these data
have not been included in Fig. 1.
CAM assays as a cancer stem cell model
Next, we assessed the relative percentage of stem cell
markers in tumors excised from the CAM xenografts.
Eight independent UM-SCC-1 primary tumors were
pooled to insure sufficient cells for stem cell analysis.
Flow analysis with the aldefluor substrate and the
DEAB inhibitor showed that 18.97 % of the total cell
population reacted with the aldefluor substrate and
were human cells and 81.03 % consisted of chick
(aldefluor fluorescence negative) cells (Fig. 2). Of the
human cell population when the ALDH inhibitor
DEAB is removed, 8.17 % were ALDHhigh (also
known as the stem cell or side population [26]) and
81.29 % were CD44high (Fig. 3). These results are con-
sistent with what we have previously observed with
CSC populations in UM-SCC-1 cells excised from a
mouse model [26, 27]. Together, these results indicate
that tumors grown in the CAM assay continue to
generate HNSCC CSCs at rates similar to those ob-
served in the murine model, thus offering an alterna-
tive to murine xenografts as an in vivo approach to
study CSCs in HNSCC.
WNT974 disrupts UM-SCC cell line xenograft growth and
metastasis
After establishing the CAM model using several of the
genetically characterized UM-SCC cell lines [14], we
sought to test the effect of WNT974 on the growth and
metastatic ability of cell lines of varying NOTCH1
mutation status and in vitro pharmacodynamic response
to WNT974: UM-SCC-11A (NOTCH1 mutant, PD re-
sponder), UM-SCC-25 (NOTCH1 frameshift mutant, PD
responder), UM-SCC-1 (NOTCH1 wildtype, PD re-
sponder), and UM-SCC-14A (NOTCH1 wildtype, PD
non-responder). Tumor weight analysis shown in Fig. 4
revealed a statistically significant decrease in primary
tumor weight between treated and untreated embryos in
UM-SCC-11A (p = 1.0 × 10-7), UM-SCC-1 (p = 0.002),
and UM-SCC-25 (p = 0.0076), the three cell lines that
previously showed in vitro pharmacodynamic responses
to WNT974 [14]. There was no difference in tumor
weights between treated and untreated embryos in
UM-SCC-14A, which correspondingly was a non-PD
responder. Furthermore, qPCR analysis of organs har-
vested from developing chicks for human ALU DNA
revealed a statistically significant reduction in liver
metastases in UM-SCC-11A (p = 2.5 × 10-5) and UM-
SCC-25 (p = 0.02) (Fig. 5). Together the data demon-
strates that WNT974 can effectively disrupt xenograft
tumor growth and liver metastasis of several UM-SCC
cell lines.
Discussion
We and others have used the CAM assay for a variety of
studies [24, 26, 27]. Here we confirmed the value of
CAM assays as short term xenograft models of HNSCC
proliferation and metastatic behavior in vivo with a var-
iety of UM-SCC cell lines. We show that nine different
UM-SCC cell lines form tumors and distant metastasis
in this system. In fact, the high rates of observed tumors
and metastases demonstrate the utility of the chick
CAM assay for in vivo study of HNSCC tumor behavior
as well as the potential for an expanded use of this pre-
clinical model for studying response to drug therapy in
head and neck cancer. Our results support the value of
this model in screening tumors with different genomic
compositions for response to new drug therapies, which
could help expedite the preclinical phase of drug devel-
opment, as well as to help identify patients who are most
likely to respond to new therapies. This study demon-
strates the generation of cancer stem cells within pri-
mary tumors grown in the CAM assay. Flow cytometric
analysis of tumor cells detected CD44high and ALDHhigh
cells at similar rates to those observed in murine model
HNSCC tumors. Our ability to detect CSCs on tumor
cells grown in the CAM assay provides opportunities for


























































































Fig. 1 CAM xenografted UM-SCC cell lines metastasize to the liver.
This figure compares the relative content human DNA in the tissue
as determined by amplified human Alu DNA sequences. The values
were calculated by comparing the Alu qPCR cycle threshold (Ct) of a
given liver specimen to the organs of non-xenografted control
animals. Each qPCR reaction was completed in quadruplicate. Error
bars are standard error of the mean
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populations, behavior, and response to drug therapies.
The CAM model has several advantages as an adjunct to
murine xenografts [24]. The CAM model is relatively in-
expensive, can be completed in approximately a 16 day
window from egg delivery until harvest and is sensitive
to metastatic spread.
In addition to evaluating CAM assays as a model of
therapeutic response, we explored the interaction be-
tween the Wnt and Notch signaling pathways in
HNSCC, specifically in the context of the anti-cancer ef-
fects of Wnt pathway inhibition in tumors with different
types of Notch pathway mutation. Given the previously
proposed inhibitory effect of the Notch pathway on Wnt
signaling [19, 20], it is possible that tumors that harbor
mutations in Notch1 have increased Wnt signaling and
are therefore more susceptible to Wnt pathway inhibition.
This is also supported by the early in vitro study of
WNT974, which revealed an enriched rate of response to
WNT974 among head and neck cancer cell lines with
Notch1 loss-of-function (LOF) mutations, suggesting that
Notch1 mutation status may play a role in responsiveness
to Wnt pathway inhibition. However, it is also possible
that Wnt gain of function mutations, which were not
tested for in the cell lines used in this study, could be the
independent driving force in tumorigenesis in the re-
sponder cell lines, resulting in the observed decreased
tumor growth and metastasis following Wnt pathway in-
hibition in three of the four cell lines tested. Lack of suffi-
cient statistical power due to the limited number of
HNSCC cell lines tested did not allow for correlation of
sensitivity of WNT974 in the CAM model to Notch 1
mutations status. However, the study provides strong,
early evidence for a potential role of WNT974 in the treat-
ment of patients with HNSCC as a significant therapeutic










Fig. 2 Analysis of ALDH positive cells in UM-SCC-1 CAM xenografts. a Flow cytometry of unstained sample of UM-SCC-1 primary tumor cells
grown in the CAM assay. b Flow cytometry of UM-SCC-1 CAM xenograft tumor cells stained with Aldefluor substrate and DEAB inhibitor. The
Aldefluor substrate only reacts with the mammalian ALDH enzyme, so inclusion of the substrate will allow the human cells to shift forward while
the chick cells will show no shift from the unstained sample. c Removal of the DEAB inhibitor results in a right-shift of the ALDH+ population.
1.55 % of the total cell population is ALDH+, but only 18.97 % of the total cell population is human cells. Therefore, 8.17 % of the UM-SCC-1 cells
in the CAM xenograft were analyzed to be ALDH+
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response in the CAM assay was seen with three of the
four tumor cell lines tested. Future experiments will
analyze the effects of WNT974 in the context of add-
itional biomarkers as well as in combination with other
agents in order to predict and improve clinical response.
Conclusion
HNSCC cell line xenograft growth, cancer stem cell dis-
tribution, metastasis and therapeutic response can be
effectively assessed in CAM assays in a manner consist-
ent with mouse xenograft assays. This allows for an
expeditious means to screen the efficacy of new therapeutic
agents across a large number of head and neck tumors
such that more time consuming mouse xenograft models
can be focused on the precision medicine protocols most
likely to advance to clinical trials. Therefore, we expect that
implementation of this model will significantly reduce the














































Fig. 4 WNT974 blocks UM-SCC-1, -11A and -25, but not -14A, CAM
xenograft growth. UM-SCC cell lines were implanted on CAM
models and treated with 1 μM WNT974 or vehicle control (DMSO)
every other day for eight days. At the conclusion of the experiment,
tumors were harvested from the CAM and weighed. We assessed
22, 33, 24 and 27 viable animals UM-SCC-1, -11A, -25 and -14A,
respectively, with half receiving vehicle control and the rest WNT974.
Averages of all groups are shown along with standard error.









































Fig. 5 WNT974 blocks liver metastasis of UM-SCC-11A and
UM-SCC-25 CAM xenografts. Livers from UM-SCC-11A and -25
CAM xenografts (from Fig. 4) were harvested at the conclusion
of the experiment and assessed for human ALU DNA sequences
by qPCR. WNT974 was administered every other day to a final
concentration of 1 μM. Livers from non-xenografted animals
were used as a negative control and Ct difference from the
median centered average of normal livers is shown. All qPCR
assays were run in quadruplicate. ** P < 0.05
Unstained sample  Stained with CD44-APC antibody
CD44+
a b
Fig. 3 Analysis of CD44 positive cells in UM-SCC-1 CAM xenografts. a Flow cytometry results of unstained sample of UM-SCC-1 primary tumor
cells grown in the CAM assay. b Flow cytometry results of UM-SCC-1 primary tumor cells stained with CD44-APC antibody. 15.44 % of the total
cell population is CD44+, but only 18.97 % of the total cell population is human cells. Therefore 81.39 % of the UM-SCC-1 cells in the CAM
xenograft are CD44+
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